Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
Fengnian ZhaoJinge ZhaoXinyuan WeiYifu ShiNanwei XuSha ZhuJunru ChenGuangxi SunJindong DaiZhipeng WangXingming ZhangJiayu LiangXu HuHaoyang LiuJunjie ZhaoZhenhua LiuLing NiePeng-Fei ShenNi ChenHao ZengPublished in: The Prostate (2024)
This study highlights KI67 positivity in prostate biopsy as a strong predictor of abiraterone efficacy in advanced PCa. These insights will assist clinicians in anticipating clinical outcomes and refining treatment decisions for PCa patients.
Keyphrases
- prostate cancer
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- radical prostatectomy
- peritoneal dialysis
- neoadjuvant chemotherapy
- prognostic factors
- palliative care
- signaling pathway
- squamous cell carcinoma
- ultrasound guided
- radiation therapy
- patient reported outcomes
- lymph node
- fine needle aspiration